Home / Data / Women's Health Trial Tracker Women's Health Trial Tracker Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.
Records 5,000
Last changed 10/10/2026
Update schedule 55 1 * * * UTC
Coverage 05/26/2000–10/09/2026 Record Record Date Vuga Group Change Status Recency Days Research Attention Score Developing an EEG Paradigm to Study Prediction Error in Anorexia Nervosa 10/12/2020 INTERVENTIONAL not-comparable 2,189.75 0 PreOperative Endocrine Therapy for Individualised Care With Abemaciclib 10/14/2020 INTERVENTIONAL not-comparable 2,187.75 0 Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery 10/14/2020 OBSERVATIONAL not-comparable 2,187.75 0 Preconception Lifestyle Interventions to Improve Future Metabolic Health (Before the Beginning) 10/14/2020 INTERVENTIONAL not-comparable 2,187.75 0 Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy 10/14/2020 INTERVENTIONAL not-comparable 2,187.75 0 Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer 10/14/2020 INTERVENTIONAL not-comparable 2,187.75 0 Impact of HPV Vaccination on Prevention of Cervical HPV Infection in Sikkim, India 10/19/2020 OBSERVATIONAL not-comparable 2,182.75 0 A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab 10/19/2020 INTERVENTIONAL not-comparable 2,182.75 0 What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer? 10/19/2020 INTERVENTIONAL not-comparable 2,182.75 0 Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men 10/20/2020 INTERVENTIONAL not-comparable 2,181.75 0 Fresh Corneal Lenticule Implantation and Autologous Serum - Case Report 10/20/2020 INTERVENTIONAL not-comparable 2,181.75 0 IORT-Breast at Medical Center Navicent Health 10/20/2020 OBSERVATIONAL not-comparable 2,181.75 0 Factors Influencing Fertility or Pregnancy Health 10/22/2020 OBSERVATIONAL not-comparable 2,179.75 0 Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery 10/22/2020 INTERVENTIONAL not-comparable 2,179.75 0 Fractional Flow Reserve and Instantaneous Free-wave Ratio Revascularization Strategies in Women 10/22/2020 OBSERVATIONAL not-comparable 2,179.75 0 The MASTER Study (MAmmary Cancer STatin ER Positive Study) 10/23/2020 INTERVENTIONAL not-comparable 2,178.75 0 Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT 10/26/2020 INTERVENTIONAL not-comparable 2,175.75 0 Registry Study of Pregnancy and Breast Cancer 10/27/2020 OBSERVATIONAL not-comparable 2,174.75 0 When to INDuce for OverWeight? (WINDOW) 10/27/2020 INTERVENTIONAL not-comparable 2,174.75 0 Prediction of Recurrence Among Low Risk Endometrial Cancer Patients 10/27/2020 OBSERVATIONAL not-comparable 2,174.75 0 Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer 10/28/2020 INTERVENTIONAL not-comparable 2,173.75 0 Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib 11/03/2020 INTERVENTIONAL not-comparable 2,167.75 0 Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants 11/04/2020 INTERVENTIONAL not-comparable 2,166.75 0 Immunological Mechanisms of Rejection in Uterine Transplantation 11/04/2020 INTERVENTIONAL not-comparable 2,166.75 0 Exercise and Cognitive (Brain) Function in Breast Cancer Patients Getting Chemotherapy After Breast Surgery 11/04/2020 OBSERVATIONAL not-comparable 2,166.75 0 Biomarkers of Endometrial Receptivity 11/06/2020 INTERVENTIONAL not-comparable 2,164.75 0 Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer 11/10/2020 INTERVENTIONAL not-comparable 2,160.75 0 Pre-operative Exercise During Neoadjuvant Chemotherapy in Patients With Breast Cancer 11/10/2020 INTERVENTIONAL not-comparable 2,160.75 0 A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation 11/12/2020 INTERVENTIONAL not-comparable 2,158.75 0 Mindfulness & Mechanisms Study 11/12/2020 INTERVENTIONAL not-comparable 2,158.75 0 Diagnostic, Therapeutic and Reproductive Aspects of Patients With Mullerian Anomalies 11/13/2020 OBSERVATIONAL not-comparable 2,157.75 0 Alopecia Prevention Scalp Cooling in Chinese Breast Cancer Patients 11/16/2020 INTERVENTIONAL not-comparable 2,154.75 0 Maternal Betaine Supplementation During Breastfeeding 11/18/2020 INTERVENTIONAL not-comparable 2,152.75 0 Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer 11/18/2020 INTERVENTIONAL not-comparable 2,152.75 0 Health Disparities on the Labor Floor 11/18/2020 OBSERVATIONAL not-comparable 2,152.75 0 Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors 11/18/2020 OBSERVATIONAL not-comparable 2,152.75 0 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) 11/18/2020 INTERVENTIONAL not-comparable 2,152.75 0 Refining Local-Regional Therapy for IBC 11/19/2020 INTERVENTIONAL not-comparable 2,151.75 0 Surgical Intervention for Refractory Granulomatous Lobular Mastitis 11/20/2020 INTERVENTIONAL not-comparable 2,150.75 0 Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer 11/20/2020 OBSERVATIONAL not-comparable 2,150.75 0 The PreQ-20 TRIAL, a Prospective Cohort Study of Patients Undergoing Prepectoral Breast Reconstruction 11/24/2020 INTERVENTIONAL not-comparable 2,146.75 0 Comparison of Hemostatic Agent to Suture in Terms of Hemostatic Function and Preservation of Ovarian Function 11/24/2020 INTERVENTIONAL not-comparable 2,146.75 0 WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC 11/25/2020 INTERVENTIONAL not-comparable 2,145.75 0 Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer 11/30/2020 INTERVENTIONAL not-comparable 2,140.75 0 Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences 12/02/2020 INTERVENTIONAL not-comparable 2,138.75 0 Effect of Vitamin D on Ovulation Rate in Women With Polycystic Ovary Syndrome 12/03/2020 INTERVENTIONAL not-comparable 2,137.75 0 GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab 12/03/2020 INTERVENTIONAL not-comparable 2,137.75 0 Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program 12/03/2020 INTERVENTIONAL not-comparable 2,137.75 0 Naprapathy Training for Postpartum DRAM Prevention 12/03/2020 INTERVENTIONAL not-comparable 2,137.75 0 Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer 12/04/2020 INTERVENTIONAL not-comparable 2,136.75 0
Source U.S. National Library of Medicine, ClinicalTrials.gov API v2 · official record · retrieved 10/10/2026 · upstream last modified 10/10/2026
Licence United States government work; public domain unless the source record says otherwise. Source: U.S. National Library of Medicine
Required notice Study records are informational and do not provide diagnosis, treatment advice, or an assessment of individual risk. What we add We compute Vuga Group, Change Status, Recency Days, Research Attention Score using the documented compute method. · methodology